Post by CVS Health

Several FDA decisions expected this spring could expand treatment options, including a first-of-its-kind treatment, a more accessible format for Alzheimer’s care, a new approach to high blood pressure and a non-nicotine option to help people quit smoking. The latest Q2 2026 Drugs to Watch report from CVS Caremark’s Clinical Pipeline Services team highlights four therapies approaching FDA review and what they could mean for patient care. Swipe for a look at the drugs to watch, then explore the full report to learn what this spring’s pipeline says about where care is headed. Which areas are you watching most closely? ⬇️ https://lnkd.in/ewrjfQyu